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Abstract
Purpose—Brivanib, an oral, multi-targeted tyrosine kinase inhibitor with activity against 
vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR) was 
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investigated as a single agent in a phase II trial to assess the activity and tolerability in recurrent or 
persistent endometrial cancer (EMC).
Patients and Methods—Eligible patients had persistent or recurrent EMC after receiving one 
to two prior cytotoxic regimens, measurable disease, and performance status of ≤2. Treatment 
consisted of brivanib 800 mg orally every day until disease progression or prohibitive toxicity. 
Primary endpoints were progression-free survival (PFS) at six months and objective tumor 
response. Expression of multiple angiogenic proteins and FGFR2 mutation status was assessed.
Results—Forty-five patients were enrolled. Forty-three patients were eligible and evaluable. 
Median age was 64 years. Twenty-four patients (55.8%) received prior radiation. Median number 
of cycles was two (range 1–24). No GI perforations but one rectal fistula were seen. Nine patients 
had grade 3 hypertension, with one experiencing grade 4 confusion. Eight patients (18.6%; 90% 
CI 9.6–31.7%) had responses (one CR and seven PRs), and 13 patients (30.2%; 90% CI 18.9–
43.9%) were PFS at six months. Median PFS and overall survival (OS) were 3.3 and 10.7 months, 
respectively. When modeled jointly, VEGF and Angiopoietin-2 expression may diametrically 
predict PFS. Estrogen receptor-α (ER) expression was positively correlated with OS.
Conclusion—Brivanib is reasonably well tolerated and worthy of further investigation based on 
PFS at six months in recurrent or persistent EMC.
Keywords
Brivanib; endometrial cancer
INTRODUCTION
Endometrial cancer (EMC) is the most common gynecologic malignancy in the United 
States and represents the vast majority (90%) of uterine corpus cancers [1]. In 2014 The 
American Cancer Society estimates 49,560 new cases of cancer of the uterine corpus with 
8,190 women dying [2]. The median survival after recurrence is 10 months and the five-year 
survival for patients who have recurred is <15%. Therapies (radiation, hormonal, 
chemotherapy, or combinations) for women with advanced stage, progressive or recurrent 
EMC are not very effective and novel therapies are desperately needed.
There have been several randomized studies addressing the issue of optimal therapy for this 
group of patients. A recently reported study randomly assigned 1350 patients to paclitaxel, 
doxorubicin, and cisplatin (TAP) versus carboplatin and paclitaxel (TC) to determine if TC 
is therapeutically equivalent. They found that TC is not inferior to TAP in terms of 
progression-free survival (PFS) and overall survival (OS) based on interim analysis results 
and the toxicity profile favors TC [3]. Once this initial therapy has been delivered, there are 
limited treatment options. Although hormonal therapies can result in responses and 
improved PFS, most often these responses are of short duration [4–5]. Other targeted 
therapies have been, or are currently being tested, but have yet to be implemented into 
routine clinical practice. The majority of completed endometrial cancer studies with targeted 
agents demonstrated minimal to modest activity including: agents that target vascular 
endothelial growth factors and receptors (VEGF(R))-sunitinib, sorafenib, and thalidomide; 
human epidermal growth factor receptor 1 and 2 - erlotinib, gefitinib cetuximab and 
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trastuzumab; and mammalian target of rapamycin - temsirolimus, everolimus, and 
ridaforolimus [6–16]. The most active is bevacizumab, an monoclonal antibody that inhibits 
VEGF-A which demonstrated a 13.5% response rate with 40.4% of patients PFS at 6 months 
[17]. Thus, further development of therapies that not only target the VEGF pathway but 
other important receptor tyrosine kinases is warranted.
The fibroblast growth factor (FGF) family comprises 18 ligands (FGF1 through FGF10 and 
FGF16 through FGF23) that signal through four transmembrane receptor tyrosine kinases 
(FGFR1-R4) and their alternatively spliced isoforms [18]. FGF signaling has been shown to 
play a crucial role in many physiological and pathological processes including 
embryogenesis, angiogenesis, and tumorigenesis [19]. Pollock and colleagues first reported 
activating mutations in FGFR2 and have since reported mutations in 48/466 (10%) 
endometrioid endometrial cancers [20,21]. This finding has been confirmed by independent 
groups at a similar frequency [22–26]. Extensive functional analyses have already been 
performed for many of the mutations, demonstrating they result in constitutive ligand-
dependent and ligand-independent receptor activation [20]. EMC cell lines with FGFR2 
activating mutations undergo cell cycle arrest and cell death in response to FGFR inhibition 
with the selective inhibitor PD173074 [27]. Considerable in vitro activity has also been 
reported for several clinically relevant anti-FGFR compounds [28–30]. Thus, FGFR appears 
to be a viable therapeutic target for patients with endometrial carcinoma.
Brivanib, an oral medication, is a dual tyrosine kinase inhibitor of VEGFR and FGFR 
signaling. Brivanib has been evaluated in multiple tumor types with promising antitumor 
activity [31,32]. A phase II trial of single-agent brivanib was conducted in patients with 
recurrent or persistent EMC. The primary objective was to evaluate efficacy in terms of both 
the probability of surviving progression free for at least six months (PFS at six months) and 
clinical response. Predictive and prognostic biomarker discovery is also incorporated in this 
trial.
PATIENTS and METHODS
Patient Selection
To be eligible the following criteria were met: histologic confirmation of the primary tumor 
by central pathology review by the Gynecologic Oncology Group (GOG) Pathology 
Committee; GOG performance status of 0–2; measurable disease by modified Response 
Evaluation Criteria in Solid Tumors (RECIST) [33]; one to two prior cytotoxic regimens; 
chemotherapy was discontinued at least three weeks before registration (hormonal therapy at 
least one week); recovery from recent surgery, radiotherapy, or chemotherapy; no evidence 
of active infection requiring antibiotics. Patients must also have had adequate hematologic 
counts (absolute neutrophil count ≥1,000/μL and platelets ≥100,000/μL), chemistries 
(hyponatremia (sodium >129), potassium (>3.4 mmol/L), serum creatinine ≤1.5× the 
institutional upper limit of normal [ULN] and urine protein <3+ or <3.5 g/24 hours, serum 
bilirubin ≤1.5× ULN and AST and alkaline phosphatase ≤2.5× ULN, albumin >=2.5 g/dl), 
and coagulation profiles (prothrombin time such that international normalized ratio ≤1.5, 
anticoagulation with low molecular weight heparins were allowed); left ventricular ejection 
fraction ≥50% and QTc on ECG <450 msec; negative pregnancy test before study entry and 
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agreement to practice an effective form of contraception in patients of childbearing 
potential. All patients signed approved informed consent in accordance with federal, state, 
and local requirements and an authorization permitting release of personal health 
information. Both central and local institutional review board approval were obtained.
Patients were ineligible if they met any of the following criteria: prior use of brivanib or 
anti-VEGF, anti-FGFR or anti-PDGFR (platelet-derived growth factor receptor) therapy; 
prior treatment with any noncytotoxic therapy (other than hormonal therapy); other 
malignancies (except non-melanomatous skin cancer) evident within three years or prior 
cancer treatment that contradicts eligibility; on required chronic anti-platelet therapy (aspirin 
>300 mg/day or clopidogrel greater than or equal to 75 mg/day); on therapeutic warfarin 
anticoagulation; gastrointestinal bleeding or any other hemorrhage/bleeding event (CTCAE 
Grade ≥ 3) within 30 days prior to study entry; history of poor wound healing, non-healing 
ulcers or bone fractures within the last three months; known brain metastasis; clinically 
significant cardiovascular disease (myocardial infarction or uncontrolled angina within 12 
months, Class III–IV New York Heart Association congestive heart failure), arrhythmias 
requiring anti-arrhythmic therapy other than beta-blockers or digoxin, valvular heart disease 
(>CTCAE grade 2); history of stroke, TIA, or other CNS ischemic event; inability to 
swallow tablets or untreated malabsorption syndrome and a serious uncontrolled medical 
disorder or active infection (active/known HIV, Hepatitis B, or Hepatitis C, hyponatremia, 
hypokalemia).
Treatment
Enrolled patients were to receive brivanib 800 mg orally daily (28 day cycle) with dose 
modification to 600 or 400 mg daily for toxicity. Treatment was planned until disease 
progression or adverse events prohibited further therapy. Toxicity was monitored with 
history, physical examination, and laboratory assessment before each treatment cycle, with 
adverse events defined and graded according to Common Terminology Criteria for Adverse 
Events (CTCAE version 3.0). Brivanib was held for grade 3 non hematologic toxicity for a 
maximum of 30 days to allow recovery to ≤ grade 1. Brivanib was discontinued for cardiac 
ischemia or infarction; evidence of cardiac valve dysfunction >CTCAE Grade 2; LVEF 
decrease by >10% from baseline-echocardiogram and LVEF <45%; QTc >500 milliseconds 
on two ECGs performed during the same visit and in the absence of possible causes other 
than protocol therapy; torsade de pointes or sustained ventricular tachycardia; hemorrhage 
>CTCAE Grade 3; gastrointestinal perforation; arterial thromboembolic events; venous 
thromboembolic events CTCAE Grade 4; seizures/convulsions thought to be possibly, 
probably or definitely related to study drug or hyponatremia; Reversible Posterior 
Leukoencephalopathy Syndrome (RPLS), Posterior Reversible Encephalopathy Syndrome 
(PRES) or similar leukoencephalopathy syndrome. Specific guidelines were implemented 
for modifying the treatment regimen in the event of liver enzyme elevation, bilirubin 
elevation, hyponatremia, hypertension, and hypothyroidism.
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Evaluation Criteria
Activity of brivanib was assessed according to RECIST criteria before each cycle by 
computed tomography or magnetic resonance imaging at baseline, every other cycle for the 
first six months, and every three months thereafter.
Translational Research
For each patient, slides from either the primary, recurrent or metastatic tumor were available 
and plasma was collected prior to cycle 1 (baseline), cycle 2 and cycle 3. Translational 
studies included sequencing of FGFR2, and immunohistochemistry of FGFR1, FGFR2, 
FGF1, FGF2, ER, PR-A, and PR-B. In addition, to explore if circulating biomarkers of 
angiogenesis were predictive of patient outcome, multiple anti-angiogenesis biomarkers in 
pre- and post-treatment serum samples were measured in duplicate using the Bio-Plex Pro 
Human Angiogenesis 9-Plex Kit (Bio-Rad Laboratories). The primary clinical/translational 
results are highlighted in this report and a detailed report of methods and analyses of these 
endpoints will be reported elsewhere.
Statistical Analysis
The primary endpoints used to evaluate the efficacy of brivanib were tumor response and 
PFS at six months. A two-stage design with co-primary endpoints was employed in the trial, 
which used the “minimum C method” as provided in Sill et al. [24] The null hypothesis (Ho) 
assumed a probability of response and PFS at six months equal to 10% and 15%, 
respectively, which was derived from a historical control. See Table 1 of Aghajanian et al. 
for details [17]. Twenty percent increases (Δ=0.20) in either proportion were deemed 
clinically significant. With 26 patients entered at the first stage, the design required more 
than three patients with responses or more than five who were PFS at six months before 
proceeding to the second stage. With a cumulative sample size of 43, the design required at 
least nine patients with responses or 11 patients PFS at six months before declaring the 
regimen worthy of further study. The study had 60–68% probability of early termination 
under Hyo, a 6.6% level of significance, and about 90% power. Secondary endpoints 
included PFS and OS. Time at risk was determined from the date of protocol entry. 
Treatment related toxicities were characterized by their frequency and severity according to 
organ or organ system affected.
Exploratory analyses of biomarkers were conducted to assess pre-treatment associations 
between biomarkers, patient demographics, and clinical outcome. Translational research 
yielded hypothesis generating questions when “p-values” were 5% or less; these were 
deemed suggestive and worthy of follow-up in future studies. Associations with 0.05<p-
value<0.10 were called “potential trends.” To screen for potential effects on PFS and OS, 
biomarker variables were often dichotomized at their median values for Cox modeling [39] 
or in log-rank tests [40]. Hazard ratios (HR) were reported for high to low levels of 
biomarkers. Exact χ2 tests were used to assess associations with strictly categorical variables 
[34].
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RESULTS
From July 2009 to January 2011, GOG member institutions enrolled 45 patients onto this 
trial. One patient was deemed ineligible because a required test was not done and another 
had the wrong primary cancer; the remaining 43 patients were assessable for toxicity and 
efficacy. Patient characteristics are listed in Table 1. A total of 191 cycles were administered 
with a median of two cycles (range, 1–24 cycles). Fifteen patients (34.9%) received ≥4 
cycles.
Activity
The clinical activity of brivanib was determined for the 43 eligible patients (Table 2). Eight 
patients (18.6%; 90% CI 9.6–31.1%) experienced clinical responses (one complete response 
(CR) and seven partial responses (PRs); median response duration, 6.3 months), and 13 
patients (30.2%; 90% CI 18.9–43.7%) were PFS at six months. Median PFS and OS were 
3.3 (90% CI 2.0 – 3.9) and 10.7 (90% CI 9.2 – 18.1) months, respectively (Figure 1). One of 
the 13 patients PFS at six months went off study therapy due to hypertensive crisis and went 
onto subsequent therapy 2.3 months after study entry. Deeming this patient a treatment 
failure, the estimated proportion PFS at six months is 27.9% (90% CI 17.0 – 41.3%). There 
was no suggested association between cell type and patient response or PFS at six months 
(Table 3).
Adverse Events
As shown in Table 4, safety of brivanib in all 43 patients was analyzed descriptively. No GI 
perforations but one rectal fistula were reported. One grade 5 event was reported. It did not 
have a specific CTC adverse event term but was listed as a multi-organ failure. The 
attribution to the treatment was listed as possible. Additionally, nine patients had grade 3 
hypertension. One of these patients had grade 4 confusion and was removed from study 
secondary to posterior reversible encephalopathy syndrome.
Translational Endpoints
Of the 32 patients for whom adequate tumor DNA was available for analysis, 3/32 (10%) 
carried activating somatic FGFR2 mutations (2x C383R; 1xN550K+R679S). Mutations 
were found in 2/16 endometrioid and 1/7 mixed histology tumors for a frequency of 13% 
(3/23) in these subtypes. From the primary tumors, there was a suggested association 
between ER expression with OS and cell type. There was a no trend indicated for improved 
PFS. Plasma collagen levels were not associated with PFS or OS. When modeled separately, 
none of the angiogenic markers were suggested as being associated with PFS and OS, 
however, a permutation test (with 10,000 simulations) using a Cox model indicated a 
potential trend for the factors angiopoietin-2 (Ang-2) and VEGF when modeled jointly. This 
analysis indicates that patients with higher levels of Ang-2 tend to have a lower risk of 
progressing (HR=0.28) and patients with higher levels of VEGF tend to have a higher risk of 
progressing (HR=3.1) (Supplemental Table 1). Patients with high levels of VEGF tended to 
have high levels of Ang-2, which may have masked these trends when the biomarkers were 
modeled individually. These results did not translate into OS as strongly but had similar 
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tendencies (Supplemental Table 2). Ang-2 had an estimated HR=0.52, and VEGF had an 
estimated HR=1.8. Sample sizes did not permit construction of reliable confidence intervals.
DISCUSSION
While early-stage endometrial cancer is often successfully treated with surgical intervention, 
treatment of advanced-stage endometrial carcinoma or recurrent disease can be difficult, and 
the prognosis is poor. The GOG has established levels of activities for targeted therapies in 
these patients based on historical controls to determine if an agent is of significant interest 
for further development [23]. Based on this assessment brivanib is worthy of further 
investigation with 30.2% of patients PFS at six months. Eight patients (18.6%) experienced 
a clinical response in this study of unselected recurrent or persistent endometrial cancer 
patients with one or two prior cytotoxic chemotherapy regimens with 56% receiving prior 
radiation therapy.
Patients receiving brivanib with endometrioid (6 of 19; 31.5%) or mixed epithelial subtypes 
(4 of 8; 50%) appeared to have the best PFS at six months compared to those with pure 
serous carcinoma (1 of 10; 10%). Interestingly, the one patient with a complete response and 
three of six patients with a partial response had serous histology. This variation in response 
may be different than that achieved with bevacizumab, where responses were seen across all 
histologic subtypes and the percentage of patients alive and progression-free at six months 
was similar for serous and endometrioid histologies [17]. The association between ER and 
OS in this study likely reflects the correlation with ER and cell type, where endometrioid 
histology has been shown in larger cohorts to be associated with a more favorable prognosis. 
In addition, ER, VEGFR and FGFR cross talk at this level of signaling, and it is possible 
that tumors with high ER depend upon downstream growth factor activity through VEGFR 
and FGFR for proliferation. In such cases, brivanib therapy may be beneficial.
Bevacizumab has shown the most significant activity of the targeted therapies tested to date 
with a 13.5% response rate and 40.4% of patients progression-free for at least six months 
[17]. The activity of brivanib is comparable with an 18% response rate and 30.2% of 
patients progression free at six months. Although brivanib was associated with some 
increased patient toxicities, it has the advantage of being an oral therapy and thus should be 
further developed for patients with endometrial carcinoma.
Attempts to identify molecular predictors of response for bevacizumab and other VEGF 
targeted compounds have been largely unsuccessful across multiple tumor types [35] 
pointing towards the complex interplay of the many molecules regulating angiogenesis 
within the tumor, the surrounding stroma and in circulation. When we jointly modeled 
circulating expression levels of VEGF and Ang-2, patients with higher levels of Ang-2 
tended to have a lower risk of progressing while patients with higher levels of VEGF were 
associated with a higher risk of progressing. This is consistent with an immunohistochemical 
study of breast cancer patients, which found that Ang-2 was not prognostically significant 
when modeled; however, the combination of high Ang-2 and high VEGF was predictive of 
significantly worse PFS than other combinations of VEGF and Ang-2 [36]. The interactions 
between these biomarkers can be explained by the fact that, at low levels of VEGF, Ang-2 is 
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anti-angiogenic and can induce endothelial cell death, but at high levels of VEGF, Ang-2 is 
pro-angiogenic and supports development of blood vessels [37]. Thus, Ang-2 is pro-
angiogenic only when VEGF levels are also high. Our result that high Ang-2 levels are 
associated with longer PFS when accounting for VEGF levels could be an artifact due to low 
patient numbers or could point to Ang-2 having different roles when associated with 
different VEGF levels.
Based on the trend identified when VEGF and Ang-2 were modeled together, we propose 
that these biomarkers should be evaluated in larger endometrial cancer patient cohorts that 
would also allow a comparison of the predictive value of various combinations of low and 
high VEGF and Ang-2. Further studies of Ang-2 and VEGF in endometrial cancer are 
warranted based on the elevation of these factors in patients with diabetes mellitus, a known 
factor for increased risk of endometrial cancer development [38].
Brivanib is predicted to be a modest FGFR2 inhibitor (IC50: FGFR2 125 nM). As such, we 
were interested to correlate clinical response with the presence of somatic FGFR2 mutations. 
FGFR2 activating mutations were identified in 3/23 (13%) tumors presenting with an 
endometrioid or mixed histology, consistent with previous studies. PFS for these three 
patients was 2.2, 1.84, and 26 months, however, the patient with the longest PFS was the 
patient that withdrew from therapy after two months due to toxicity. Subsequent in vitro 
studies have revealed that brivanib has relatively weak anti-FGFR activity in vitro and in 
vivo compared to other multi-kinase inhibitors [28] and more specific FGFR inhibitors 
(unpublished data, Pollock laboratory). Therefore the lack of efficacy of brivanib in these 
three patients should not be construed as evidence that FGFR2 is not a viable therapeutic 
target. Results from the ongoing trial testing dovitinib in advanced or metastatic endometrial 
cancer patients with and without FGFR2 mutations may shed light on this question. 
However, significant clinical responses may require more potent and more specific FGFR 
inhibitors. Given the efficacy of anti-angiogenic agents in endometrial cancer, it will be 
interesting to see whether prolonged clinical responses in FGFR2 mutant patients are seen 
with more specific inhibitors or those with additional angiogenic activity.
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Figure 1. 
Progression-free and overall survival for the 43 evaluable patients
Progression-free survival (PFS) and overall survival (OA) for patients treated with brivanib. 
The median PFS was 3.3 months (90% CI 2.0 – 3.9 months). The median OS was 10.7 
months (90% CI 9.2 – 18.1 months).
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Table 1
Patient and cancer characteristics
Characteristic Category No. (%)
Age 40–49 3 (7.0)
50–59 12 27.9
60–69 15 34.9
70–79 11 25.6
80–89 2 4.7
Race African American 4 9.3
White 39 90.7
Performance Status 0 28 65.1
1 12 27.9
2 3 7.0
Cell Type Clear Cell Carcinoma 5 11.6
Endometrioid Adenocarcinoma 19 44.2
Mixed Epithelial Carcinoma 8 18.6
Undifferentiated Carcinoma 1 2.3
Serous Adenocarcinoma 10 23.3
Cell Type/Grade Endometrioid, grade 1 7 16.3
Endometrioid, grade 2 4 9.3
Endometrioid, grade 3 8 18.6
Serous 10 23.3
Clear Cell 5 11.6
Mixed Epithelial 8 18.6
Undifferentiated 1 2.3
Prior Chemotherapy 1 Prior Regimen 26 60.5
2 Prior Regimens 17 39.5
Prior Radiation No 19 44.2
Yes 24 55.8
Prior Surgery No 3 7.0
Yes 40 93.0
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Table 2
Clinical Activity of brivanib
Characteristic Category No. % of
Response1 Complete response 1 2.3
Partial response 7 16.3
Stable disease 12 27.9
Increase disease 15 34.9
Indeterminate 8 18.6
PFS > 6 Months1 No 30 69.8
Yes 13 30.2
PFS to Next Rx > 6 Months No 31 72.1
Yes 12 27.9
Cycles of Treatment 1 6 14.0
2 18 41.9
3 4 9.3
4+ 15 34.9
1Six patients had both response and progression free survival (PFS) at 6 months (OR=12; 90% CI 2.0 – 90.9). The one patient who was PFS at 6 
months but began another therapy at after 2.3 months had a best response of stable disease. Rx=anti-cancer therapy.
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Table 3
Relationship of histologic sub-type and progression-free survival (PFS)
PFS>6Months
No Yes Total
Clear Cell Carcinoma 4 1 5
Endometrioid Adenocarcinoma 13 6 19
Mixed Epithelial Carcinoma 4 4 8
Undifferentiated Carcinoma 0 1 1
Serous Adenocarcinoma 9 1 10
Total 30 13 43
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